Merida Biosciences
Series A in 2025 
Merida Biosciences is a biotechnology company specializing in the development of precision therapies for autoimmune diseases. It employs a protein engineering platform to create novel Fc therapeutics, which selectively target and neutralize specific antibodies, aiming to treat the root cause of antibody-driven diseases with high precision and durability.
Layer Health
Series A in 2025 
Layer Health is a technology company specializing in AI-driven healthcare information solutions. It develops an AI-powered platform designed to help healthcare providers extract valuable insights from patient data, enabling them to make informed decisions, enhance patient care, and improve operational efficiency. The platform focuses on processing unstructured data from clinical, administrative, and research sources, transforming it into actionable insights.
Perceive Pharma
Series A in 2025 
Perceive Pharma operates as a pharmaceutical company. Perceive Pharma develops innovative small molecule neuroprotective treatments.
Apptronik
Series A in 2025 
Apptronik specializes in developing humanoid robots designed for various real-world applications. Their robots are capable of handling tasks typically performed by humans, such as case picking, down stacking, trailer unloading, palletizing, sortation, and heavy lifting. This enables industries to address labor shortages, improve job satisfaction, and enhance efficiency.
Perfumeo
Funding Round in 2025 
Perfumeo develops an AI-powered smart home fragrance diffuser that adapts scents to user moods, creating personalized fragrance experiences. The device integrates with smart home systems and uses advanced technology to store and release multiple scent capsules.
Rhygaze is a biotechnology company focused on developing innovative gene therapies aimed at restoring vision in individuals affected by blindness-related diseases. The company’s therapy utilizes advanced technology to deliver a light-sensor gene directly to cone cells that have lost their light sensitivity. By repairing these cells' ability to detect light, Rhygaze seeks to enable effective vision restoration for patients. Through its specialized approach, the company aims to make significant contributions to the healthcare industry and improve the quality of life for those facing vision loss.
Terradot is a company that specializes in developing a carbon removal platform aimed at reducing carbon footprints and transforming soil carbon management. The platform employs various methods to extract carbon dioxide from the atmosphere and enhance high-integrity soil carbon removal. By doing so, Terradot enables both businesses and individuals to actively participate in environmental stewardship, contributing to efforts to mitigate climate change and improve ecological health. The company's innovative approach seeks to create significant positive impacts on the environment through effective carbon management solutions.
Lawhive Associates
Series A in 2024 
Lawhive Associates offers legal services in civil and criminal matters, international arbitration, dispute resolution, and defamation cases.
Lawhive is a legal technology company offering an AI-powered platform designed to streamline workflow management, compliance, and payments for lawyers. This enables significant time savings for legal professionals and substantial cost efficiencies for their clients.
Synapticure
Series A in 2024 
Synapticure specializes in providing remote, disease-specific neurological care for patients with neurodegenerative diseases such as dementia, Parkinson's, and ALS across the United States. Founded by patients, they offer on-demand neurologists, speech-language therapists, round-the-clock care coordination, and support services tailored to each patient's needs.
Tessl is a technology company that specializes in AI-native software development. It offers an AI-powered platform that generates, maintains, and tests code, ensuring high-quality, secure, and self-maintaining software tailored to users' requirements. This platform is designed to be modular, scalable, and future-proof, allowing developers to create software that is compatible with emerging AI technologies.
Odyssey operates as an AI start-up, provides hollywood-grade visual AI.
Diverge Health
Series A in 2024 
Diverge Health equips primary care practices with tools and support to deliver quality healthcare services to underserved patient populations.
Genie AI is a London-based legal tech company offering an AI-powered platform for drafting contracts. Its product SuperDrafter leverages the knowledge of a law firm to accelerate drafting, while Anonymiser redacts sensitive information. The platform understands contracts semantically and supports smart contract development. Genie AI also provides educational talks and practical training on smart contracts to improve risk management and efficiency. Founded in 2017, the company serves law firms seeking faster, more accurate contract workflows and exploration of smart contract adoption.
Rippl Care
Series A in 2024 
Rippl Care is a mental health company based in Seattle, Washington, dedicated to supporting seniors experiencing dementia and other neurocognitive disorders. Founded in 2021, the company employs a value-based approach and innovative technology to deliver comprehensive care tailored to individual needs. By prioritizing the empowerment of its clinicians, Rippl Care adopts a novel care model that enables seniors to receive personalized support through various channels, including phone, online, and in-home visits. This commitment to enhancing the quality of care for those affected by neurocognitive conditions sets Rippl Care apart in the mental health landscape.
Wealth.com
Series A in 2024 
Wealth.com is a digital platform empowering individuals to create, manage, and visualize their estate plans securely. It aggregates assets, offers guidance for updates, and provides emergency access to beneficiaries. The platform also serves as an employee benefit for companies aiming to enhance financial wellness.
Pelage Pharma
Series A in 2024 
Pelage Pharma delivers a clinically tested treatment for both men and women battling the emotional pain or social stigma of hair loss. Its non-invasive, topical small molecule drug platform activates hair follicle stem cells and stimulates robust hair growth.
Again operates as a developer of advanced emission control technology that transforms carbon dioxide into valuable chemicals and proteins through a proprietary bacterial process. The company captures CO2 emissions from industrial facilities within a bioreactor, where the bacteria convert the greenhouse gas into products like feed for poultry and aquaculture. This innovative approach not only helps clients reduce their environmental impact but also allows them to avoid costly emission taxes. As a pioneer in carbon negative manufacturing, Again is positioned to meet global demand for sustainable chemical solutions while actively contributing to the fight against climate change.
Climate X
Series A in 2024 
Climate X is a global climate physical risk data analytics company that specializes in climate risk management services. The firm provides tools to project and predict the impacts of climate change and extreme weather events by integrating climate models with current real-world data. Through its physical modeling capabilities, Climate X enables businesses and governments to anticipate regulatory requirements and adapt to evolving climate-related challenges. Its clientele includes prominent financial institutions in sectors such as banking, real estate, and insurance, highlighting its relevance in a rapidly changing climate landscape.
Verse provides software for organizations to understand, plan, and manage clean energy. Its SaaS platform, Aria™, leverages generative AI to help companies define clean energy goals and plan, procure, and manage optimal portfolios of clean energy assets at least cost. Customers can set parameters that target specific goals (e.g., cost, emissions, or hourly matching) and optimize for annual matching, emissions matching, or hourly matched carbon-free energy (CFE). By reducing transaction costs by up to 70% and providing real-time analysis within minutes, Aria helps scale and accelerate the clean energy transition.
WitnessAI
Series A in 2024 
WitnessAI develops a security platform that empowers enterprises to safely adopt and utilize generative AI. Its solution ensures visibility, privacy, and governance controls, enabling businesses to innovate while maintaining control over their AI activities.
Delphia Therapeutics
Series A in 2024 
Delphia Therapeutics, headquartered in Boston, USA, is a biotechnology company focused on cancer therapeutics. It operates a laboratory dedicated to studying cancer-driving pathways and developing treatments that target and over-activate specific cancer-linked cell signaling, ultimately leading to the death of tumor cells.
Metsera is a clinical-stage biopharmaceutical company specializing in developing innovative therapies for obesity and metabolic conditions. It focuses on advancing oral and injectable treatments, integrating proprietary health technology tools for personalized care.
Pelage Pharma
Series A in 2024 
Pelage Pharma delivers a clinically tested treatment for both men and women battling the emotional pain or social stigma of hair loss. Its non-invasive, topical small molecule drug platform activates hair follicle stem cells and stimulates robust hair growth.
Lapse is a social disposable camera application that allows users to capture and share photos in a nostalgic format reminiscent of traditional disposable cameras. The app facilitates private group chats where users can take up to 36 snapshots, creating a "roll" that is only accessible to group members for a limited time after the first image is taken. This design encourages spontaneity and a sense of shared experience among friends, promoting an engaging way to document moments together while maintaining privacy.
Fabric is a health tech company that enables healthcare providers to deliver faster, higher quality, and more accessible care while reducing costs via consumer-grade patient experiences that automate workflows for staff.
Areteia Therapeutics
Series A in 2024 
Areteia Therapeutics is a biotechnology company focused on developing oral therapies for eosinophilic asthma to improve disease control. The company was spun out of Knopp and is advancing an oral drug designed to inhibit eosinophil maturation, aiming to reduce inflammation and alleviate symptoms of severe asthma. Phase 2 data from its program indicated the oral candidate lowers blood eosinophil counts, a marker associated with better lung function. By pursuing an oral, non-injectable treatment option, Areteia seeks to offer a convenient alternative to injectable therapies and broaden access for asthma patients. The company’s work centers on targeting eosinophil-related pathways to enhance asthma management and patient quality of life.
Granata Bio
Series A in 2024 
Granata Bio is a biotechnology company established in 2018 that specializes in identifying and developing therapeutics for fertility patients. The company focuses on creating a comprehensive portfolio of fertility-related treatments and leverages its expertise in commercialization, late-stage clinical trials, and regulatory development. Granata Bio aims to address significant challenges faced by medical professionals in fertility treatment. Recently, the company announced a partnership with IBSA Institut Biochimique to co-develop a novel subcutaneous progesterone solution, further enhancing its commitment to improving fertility care.
Flutterflow
Series A in 2024 
FlutterFlow, founded in 2020, is an innovative low-code, visual development platform that facilitates the creation of native mobile and web applications. With a user base exceeding 400,000 and thousands of applications successfully deployed to app stores, the platform allows product teams to design appealing user interfaces and produce clean code efficiently. It features a one-click deployment option that significantly reduces launch times while maintaining the ability to incorporate custom code. FlutterFlow's capabilities include seamless integration with Firebase and the ability to download generated Flutter code, enabling developers to build cross-platform applications quickly. This advanced platform streamlines the application development process, allowing businesses to scale rapidly and effectively.
Moonwalk Biosciences
Series A in 2024 
Moonwalk Biosciences is a genomic medicine startup focused on developing precision epigenetic therapeutics. The company specializes in creating a profiling and engineering technology platform that leverages advanced artificial intelligence predictions to offer a comprehensive view of the epigenome in both health and disease states. This innovative approach aims to revolutionize therapy discovery and development, enabling healthcare providers to reprogram cells back to their healthy state.
Essential AI
Series A in 2023 
Essential AI develops AI solutions that automate labor-intensive tasks, enhancing efficiency. Its Large Language Models empower users to handle complex tasks, unlocking essential skills and amplifying organizational impact.
Tome Biosciences
Series A in 2023 
Tome Biosciences is a biotechnology company specializing in programmable gene insertion technology. Utilizing CRISPR, the company develops methods to insert genetic sequences of any size at various locations within any genome. This innovative approach aims to enhance the ability to detect and eliminate deoxyribonucleic acid from similar bacteriophages during infections. By advancing cell and genome engineering, Tome Biosciences seeks to provide effective therapeutic solutions for patients, paving the way for significant advancements in genetic medicine.
Gate Bioscience
Series A in 2023 
Gate Bioscience is a biotechnology company focused on developing small molecule drugs aimed at treating challenging diseases by selectively eliminating harmful extracellular proteins at their source within cells. The company utilizes a unique library of molecular gates along with specialized secretion-focused assays and technologies, leveraging its deep understanding of the biology of the secretory pathway. This approach facilitates precise, rapid, and repeatable drug discovery, allowing for the potential to address a diverse array of diseases using a single therapeutic mechanism.
Allara Health
Series A in 2023 
Allara Health is a healthcare provider specializing in virtual care for women facing complex, chronic health conditions, particularly polycystic ovary syndrome (PCOS). The company offers a comprehensive program that connects patients with medical providers and registered dietitians through virtual appointments. Allara's services include holistic care, diagnostic testing, and prescriptions, along with personalized guidance on dietary and lifestyle changes. By leveraging technology, the platform enables women to efficiently manage their health, allowing for improved tracking and treatment of their conditions.
Midi Health
Series A in 2023 
Midi Health is a virtual care clinic specializing in women's health. It offers personalized treatment protocols for depression, gynecological cancer, and menstrual issues, delivered by clinicians trained in female midlife health. The platform leverages at-home labs, prescription medications, supplements, and lifestyle coaching to provide comprehensive care.
Optiwatt is a software company that connects home electricity rate data with electric vehicle (EV) battery metrics. It securely integrates with EV apps, automatically finds users' utility costs based on their home address, and calculates the impact of charging on electric bills. Additionally, Optiwatt offers charge forecasting to alleviate range anxiety by accurately predicting savings from driving electric using real-time electricity rates and local gas prices.
EpiBiologics
Series A in 2023 
EpiBiologics is a biotechnology company focused on developing antibody-based targeted therapies aimed at membrane and extracellular proteins that contribute to various diseases. Utilizing its proprietary EpiTAC platform, EpiBiologics creates therapeutics designed to degrade these disease-driving proteins, addressing the underlying biology of a wide range of disorders. The company's innovative approach enables researchers to manipulate cellular proteostasis, offering potential advancements in the treatment of challenging health conditions.
Resistant AI
Series A in 2023 
Resistant AI is a technology company that provides risk management software for machine learning systems and digital financial services. Its offerings focus on protecting automated financial platforms from adversarial manipulation and fraud, including document fraud detection and transaction monitoring. The company helps banks, insurance companies, payment platforms, and lenders secure digital transactions and perform identity forensics to guard against manipulation by organized fraudsters. By combining ML risk detection with ongoing monitoring, Resistant AI aims to enable responsible deployment of AI and machine learning while identifying, managing, and resolving risks associated with AI adoption and automated finance.
Caraway is a digital healthcare company focused on providing integrated mental, reproductive, and physical healthcare services specifically for college women. Designed with input from students, Caraway delivers a personalized and equitable care solution that addresses the unique needs and concerns of women during a crucial developmental period. The platform emphasizes accessible and compassionate healthcare, recognizing the growing demand for mental health resources and the persistent inequities in women's health. By offering trusted and holistic care, Caraway empowers college students to effectively manage their health in a complex and often challenging healthcare landscape.
Delve Bio
Series A in 2023 
Delve Bio is a biotechnology company that provides molecular insights to guide precision patient care, offering pathogen-agnostic and unbiased detection of neuro-infectious pathogens in cerebrospinal fluid to enable laboratories and clinicians to diagnose routine and rare infectious diseases with actionable results.
Bitterroot Bio
Series A in 2023 
Bitterroot Bio specializes in developing innovative therapies for cardiovascular disease by harnessing the power of immunotherapy.
Comanche Biopharma
Venture Round in 2023 
Comanche is a biopharmaceutical company developing an investigational siRNA medicine for preterm preeclampsia. Its mission is to provide safe, effective, evidence-based, and affordable therapies for treating life-threatening complications of pregnancy.
Push Security
Series A in 2023 
Push Security is a cybersecurity software company focused on protecting identities and preventing identity-based attacks. It provides a browser-based agent that observes how employees use and create identities, generating telemetry that can be viewed in the Push platform or forwarded to SIEM or SOAR systems. The software enables security teams to monitor and secure the entire identity attack surface and detect and block identity-based threats, including advanced phishing techniques. It enforces in-browser controls to block, warn, or guide employees to prevent breaches. The solution also offers clear, step-by-step guidance on implementing essential security controls and uses automation to accelerate deployment, helping organizations improve security without adding costly tools or complex deployments.
EpiBiologics
Series A in 2023 
EpiBiologics is a biotechnology company focused on developing antibody-based targeted therapies aimed at membrane and extracellular proteins that contribute to various diseases. Utilizing its proprietary EpiTAC platform, EpiBiologics creates therapeutics designed to degrade these disease-driving proteins, addressing the underlying biology of a wide range of disorders. The company's innovative approach enables researchers to manipulate cellular proteostasis, offering potential advancements in the treatment of challenging health conditions.
dope.security
Series A in 2023 
Dope Security is a stealth technology company focused on developing enterprise cybersecurity software that addresses web-based threats. Its innovative platform eliminates the traditional data center architecture used by legacy providers by implementing a fly-direct approach that secures data directly at the endpoint. This method enhances performance while ensuring privacy and reliability for enterprises. The company aims to provide a seamless user experience, making it easier for cybersecurity firms to protect their clients from various online vulnerabilities.
MedTourEasy
Series A in 2023 
MedTourEasy, a global healthcare company, provides you the informational resources needed to evaluate your global options. MedTourEasy provides analytical solutions to our partner healthcare providers globally.
Santa Ana Bio
Series A in 2023 
Santa Ana Bio is a biotechnology company specializing in the development of precision immunology therapies for autoimmune diseases. It employs advanced multi-omics platforms and antibody engineering techniques to design targeted biologics, aiming to improve patient outcomes and quality of life.
Typeface is a generative AI application for creating enterprise content. It enables organizations to accelerate the production of on-brand content by combining speed, brand personalization, and governance across the content lifecycle. The platform offers self-service content development tools that cover the entire lifecycle, enabling employees to craft content with ease, speed, and brand authenticity while maintaining consistency. Typeface provides proactive suggestions to improve content and helps enterprises uphold brand standards as content scales across teams.
Aera Therapeutics
Series A in 2023 
Aera Therapeutics is a biotechnology company focused on advancing genetic medicines through its proprietary protein nanoparticle (PNP) delivery platform. This innovative platform utilizes endogenous human proteins derived from retroelements, which self-assemble into capsid-like structures capable of packaging and transferring nucleic acid cargo. By addressing the limitations of current delivery technologies, Aera aims to enhance the efficacy and reach of genetic therapies across various tissues and disease areas. Additionally, the company holds a licensed technology that features a therapeutic enzyme platform based on novel, compact, and programmable gene-editing enzymes, further expanding its capabilities in the field of genetic medicine.
Superplastic
Series A in 2023 
Founded in 2017, Superplastic is a Vermont-based company that creates character-based products and entertainment. It designs limited edition art toys, apparel, games, and animation, collaborating with renowned artists to bring unique characters to life.
Paradigm is rebuilding the clinical research ecosystem by developing a platform that allows all patients equitable access to trials while improving trial efficiency and lowering barriers to participation for healthcare providers. It is an innovative company that is dedicated to transforming the clinical research ecosystem. Their mission is to create a more accessible and equitable healthcare system by developing a platform that enables patients from diverse backgrounds to participate in clinical trials.
Clinical trials are essential for testing and developing new drugs, therapies, and medical devices, but historically, they have been plagued by inefficiencies, barriers to access, and inequities in patient representation. Paradigm aims to solve these challenges by creating a platform that uses technology and data-driven insights to streamline the clinical trial process, making it more efficient, cost-effective, and inclusive.
The Paradigm platform is designed to facilitate seamless communication and collaboration among all stakeholders involved in clinical research, including patients, healthcare providers, pharmaceutical companies, and regulatory agencies. By leveraging technology such as AI, machine learning, and predictive analytics, Paradigm can identify and match eligible patients to clinical trials, streamline the recruitment and enrollment process, and provide real-time data insights to all stakeholders.
Overall, Paradigm's innovative approach to clinical research has the potential to revolutionize the healthcare industry by improving patient outcomes, reducing healthcare costs, and accelerating the development of new treatments and therapies.
Osmo
Venture Round in 2023 
Osmo is a technology company that equips computers with the ability to sense smell using advanced AI and olfactory science. Initially focused on enhancing fragrance products, Osmo's long-term goal is to improve human health and well-being through innovative applications of smell detection.
Cacheflow
Series A in 2022 
Cacheflow is a San Francisco-based no-code platform that streamlines SaaS sales from quote to payment. The B2B software helps firms generate dynamic quotes, offer self-service checkout, and process integrated payments, reducing the time from proposal to purchase. It also provides automated billing and flexible payment options, including monthly, quarterly, and deferred plans, to improve cash flow and strengthen client relationships. By consolidating selling and buying workflows into a single system, Cacheflow enables SaaS businesses to sell more quickly and efficiently.
Contraline
Series A in 2022 
Contraline, Inc. is a biotechnology company based in Charlottesville, Virginia, focused on developing innovative male birth control solutions. The company is pioneering the first long-lasting, non-hormonal, and reversible contraceptive for men. Its primary product, Echo-V, is an ultrasound-visible polymer solution that is injected into the vas deferens, forming a polymer hydrogel device. This device functions as a semi-permeable membrane, effectively blocking sperm while allowing bodily fluids to pass through. Contraline also offers Vasintomy, a non-surgical procedure for the insertion of Echo-V, providing a cost-effective and accessible approach to male contraception. Incorporated in 2015, Contraline aims to transform the landscape of reproductive health for men.
Sidequest
Series A in 2022 
Sidequest Ltd., established in 2020 and headquartered in Belfast, UK, operates as a platform enabling the distribution of early access content to users within the realm of virtual reality computer games.
Pretzel Therapeutics
Series A in 2022 
Pretzel Therapeutics is a biotechnology company focused on developing therapies for mitochondrial dysfunction. Founded by leading experts in mitochondrial biology, the company aims to address the underlying causes of mitochondrial dysfunction through a thorough understanding of mitochondrial mechanisms. By creating innovative treatments, Pretzel Therapeutics seeks to provide effective solutions for a range of diseases, particularly those related to aging. The company is dedicated to advancing the field of mitochondrial medicine and improving patient outcomes through targeted therapeutic approaches.
Omni is a technology company specializing in business intelligence platforms. It offers a unique solution that combines the consistency of a shared data model with the flexibility of SQL, enabling users to efficiently analyze and share reliable metrics while avoiding unnecessary complexity.
Twid is India's first rewards-based payment network, established in Bengaluru in October 2020. The company offers a digital platform that consolidates various rewards points from different issuers, including banks and brands, into a single application. This integration allows consumers to access and utilize their accumulated rewards for everyday payments across a wide range of merchants, which includes over 50,000 live retail partners, online services, restaurants, and travel aggregators. Twid aims to make rewards points universally applicable, enabling customers to freely use their points as a currency for transactions. The company was co-founded by Amit Koshal, Rishi Batra, and Amit Sharma, both of whom have extensive experience in leadership roles within the tech and investment sectors. With a customer base exceeding 40 million, Twid is positioned to revolutionize how consumers engage with their rewards systems.
Vicinitas Therapeutics
Series A in 2022 
Vicinitas Therapeutics is a biotech startup that specializes in developing medicines that impact patient lives. Its vision is to use its proprietary Deubiquitinase Targeting Chimera (DUBTAC) platform to restore the levels of aberrantly degraded proteins that cause disease to confer therapeutic benefit.
Xilis, Inc. is a biotechnology company founded in 2019 and based in Chapel Hill, North Carolina. The company specializes in developing next-generation organoid technologies aimed at guiding precision therapy for cancer patients and enhancing drug discovery processes. Its flagship platform, XilisµO, facilitates rapid diagnostics, personalized drug screening, and the creation of scalable patient-derived models, which support high-throughput drug discovery. By enabling both physicians and pharmaceutical companies to conduct tailored drug screenings, Xilis aims to lower costs and improve treatment outcomes for cancer patients.
Areteia Therapeutics
Series A in 2022 
Areteia Therapeutics is a biotechnology company focused on developing oral therapies for eosinophilic asthma to improve disease control. The company was spun out of Knopp and is advancing an oral drug designed to inhibit eosinophil maturation, aiming to reduce inflammation and alleviate symptoms of severe asthma. Phase 2 data from its program indicated the oral candidate lowers blood eosinophil counts, a marker associated with better lung function. By pursuing an oral, non-injectable treatment option, Areteia seeks to offer a convenient alternative to injectable therapies and broaden access for asthma patients. The company’s work centers on targeting eosinophil-related pathways to enhance asthma management and patient quality of life.
FYTO, Inc. is a company based in Cambridge, Massachusetts, founded in 2019, that specializes in the development of plant-based feed production systems. The firm focuses on creating nutrient-dense crops and innovative cultivation and harvesting systems designed to enhance agricultural quality and consistency. FYTO's offerings include a variety of agricultural products such as animal feed, fodder, plant-based proteins, nutritional supplements, and bio-fertilizers. By employing climate-friendly methodologies, the company aims to improve both the economic and environmental sustainability of agriculture, providing personalized solutions to farmers worldwide that promote ultra-high yields while minimizing resource requirements.
Flexidao develops software that uses blockchain technology to trace and certify electricity from production to consumption. This enables businesses to understand the carbon footprint of their energy usage, facilitating the procurement of cleaner electricity and driving operational decarbonization.
Sanas operates as a real-time speech understanding platform, specializing in accent modulation technology. Its core product enables multilingual speakers to communicate effectively by correcting accents while preserving voice and emotional nuances. This innovation benefits contact centers and enterprises by enhancing communication, boosting customer satisfaction, and minimizing misunderstandings due to language barriers.
Ahana, founded in 2020 and based in San Mateo, California, specializes in developing ad hoc analytics solutions using PrestoDB. The company aims to make interactive analytics more accessible by simplifying the process for organizations of various sizes. Ahana also works to promote growth within the Presto community, building on its widespread use at large internet companies like Facebook, Uber, and Twitter.
Strella Biotechnology
Series A in 2022 
Strella Biotechnology, founded in 2018 and headquartered in Philadelphia, Pennsylvania, focuses on enhancing the freshness of produce throughout the supply chain. The company specializes in designing and manufacturing sensors that detect ethylene gas, a key indicator of ripeness in fruits. By measuring ethylene production, Strella's technology helps optimize freshness and minimize spoilage. The company leverages its proprietary sensing technology to provide valuable data for improving supply chain management in the food industry.
Deepset is a technology company that specializes in natural language processing (NLP) solutions, providing tools and frameworks for enterprise AI teams. Established in 2018, the company is known for its Haystack open-source framework, which facilitates the development of NLP applications. Deepset's software leverages advancements in machine learning and transfer learning to enable users to extract value from diverse text sources and create customized models with reduced training data requirements. Through its offerings, deepset has supported numerous AI teams worldwide in applying cutting-edge NLP technologies to practical, real-world challenges. Additionally, the company provides deepset Cloud, an LLM platform that enhances collaboration and efficiency for enterprises focused on AI development.
Doppler provides centralized secret management software that securely stores and manages sensitive data such as API keys, credentials, environment variables, and database URLs. The platform supports multiple languages and infrastructure, enabling developers and security teams to keep secrets and application configurations in sync across projects, environments, and teams. It references frequently used secrets and uses a command-line interface to fetch the correct secrets based on the current project directory, while delivering security alerts and visibility to help prevent configuration issues. Founded in 2018, Doppler is headquartered in California and serves organizations seeking to improve developer productivity and security through centralized secret management.
Waltz Health
Series A in 2022 
Waltz Health is a company focused on innovating the pharmaceutical supply chain by developing technology-driven solutions for pricing, distribution, and prescription of medications. It collaborates with various partners, including consumers, payers, and pharmacies, to create smarter ways to manage prescription care. The company utilizes AI-driven marketplaces to reduce costs and offers consumer tools that enhance decision-making regarding healthcare. These tools provide users with better pricing, comprehensive information, and resources aimed at lowering expenses, empowering consumers, and enabling payers to effectively manage their pharmacy benefits. Through these efforts, Waltz Health strives to improve the overall experience and affordability of prescription medications.
Rooser is a European B2B platform that connects seafood buyers and suppliers. It streamlines trading processes by facilitating price negotiations and delivery management.
Gravity Sketch
Series A in 2022 
Gravity Sketch develops intuitive multi-platform tools for three-dimensional (3D) creation, collaboration, and design. Founded in 2014, the company is headquartered in London, UK.
Rattle develops a Salesforce integration technology that enables seamless interaction between systems and people within Slack or Teams. It is a revenue orchestration platform serving all customer-facing departments by allowing sales representatives to log calls, track metrics, update opportunities, and providing real-time pipeline visibility.
Agolo is a technology company that builds an artificial intelligence driven platform to create real-time summaries from unstructured information. The platform leverages machine learning and natural language processing to convert messy data into a clean entity-graph based data store, powering enterprise use cases such as GenAI applications, large language models, RAG pipelines, business intelligence dashboards, support-site augmentation, and enterprise search. By providing concise, contextual summaries, the solution helps improve product quality, reduce support costs, and enable faster detection of emerging issues. The company, originally known as Ninoh, is based in New York.
Overview.ai
Series A in 2022 
Overview’s inspection systems are built with Deep Learning technology which allows us to find mistakes more consistently and in a wider variety of situations.
Voltron Data
Series A in 2022 
Voltron Data develops tools to enhance the existing data analytics ecosystem. It focuses on improving efficiency by creating modular and composable analytics building blocks.
Neo.tax develops tax automation software for filing and optimizing tax credits. Based in Mountain View, California, the company builds tools that automate data collection from emails, documents, project management tools, and financial systems, and generate reports detailing activities, expenses, and methodologies used to claim tax credits such as the R&D tax credit. The platform aims to improve accuracy and speed in the tax filing process, helping finance teams at startups to larger companies understand evolving tax rules, including changes to R&D capitalization, and to optimize their tax liability. By combining machine learning and integrated data sources, Neo.tax seeks to provide audit-ready documentation and reduce manual effort in tax preparation.
Seismic Therapeutic
Series A in 2022 
Seismic Therapeutic is a biotechnology company focused on advancing immunology drug development through the integration of machine learning in the biologics discovery process. Utilizing its proprietary IMPACT™ platform, Seismic Therapeutic addresses critical challenges in the development of biologics by combining machine learning with structural biology, protein engineering, and translational immunology. This innovative approach aims to create optimized therapies for patients more efficiently. The company is developing a pipeline of biologics specifically targeting adaptive immune system dysregulation to treat various autoimmune diseases.
TenSixteen Bio
Series A in 2022 
TenSixteen Bio is a biotechnology company dedicated to developing innovative therapeutics targeting various diseases. It leverages somatic mosaicism and clonal hematopoiesis (CHIP) to discover and advance treatments for age-related disorders.
Carry1st is a full-stack publisher of mobile social games and interactive content focused on frontier markets, particularly Africa. Founded in 2018, it handles publishing, distribution, localization, user acquisition, marketing, monetization, and customer experience for partner games, enabling developers to reach new audiences through global studios. The company operates with a global team across multiple countries and collaborates with leading studios to grow its portfolio in untapped markets. It has raised capital from notable investors, including Riot Games and others, to fund growth and partnerships.
Wonder is a technology company that develops an all-in-one gaming platform for Android mobile devices. The platform enables users to play, stream, and share games across devices seamlessly.
Signos is a health technology company focused on addressing the obesity epidemic by promoting healthy habits and stabilizing glucose levels through innovative solutions. The company offers a weight loss application that leverages continuous glucose monitoring in conjunction with an AI-enhanced platform. This combination provides users with real-time data and personalized recommendations for meals and exercises tailored to their unique metabolic responses. By enabling individuals to better understand their body's reactions to food, Signos aims to facilitate effective weight loss and foster sustainable health improvements. With a significant portion of the American population facing weight-related challenges, Signos presents a modern approach to support users on their journey towards healthier living.
Patina is a healthcare company reinventing primary care for older adults by delivering a human, personalized, on-demand care model designed to improve the healthcare and aging experience for seniors and their families. The approach centers on the specific needs and values of aging individuals, offering flexible access to care and enabling families and loved ones to participate as part of the care team. By focusing on dignity in aging and a coordinated, person-centered experience, Patina aims to align medical care with daily living and the goals of aging adults.
Superplastic
Series A in 2021 
Founded in 2017, Superplastic is a Vermont-based company that creates character-based products and entertainment. It designs limited edition art toys, apparel, games, and animation, collaborating with renowned artists to bring unique characters to life.
Modern Age
Series A in 2021 
Modern Age is a health and wellness platform focused on simplifying the aging process for individuals. The company develops health monitoring software that utilizes computer vision and machine learning to assess skin, hair, and bone health. By collecting data from smart devices, Modern Age creates a comprehensive digital profile of an individual's health and daily activities. This information enables the platform to provide personalized recommendations and treatments, empowering users to manage their well-being more effectively and adopt healthier lifestyles as they age.
Resistant AI
Series A in 2021 
Resistant AI is a technology company that provides risk management software for machine learning systems and digital financial services. Its offerings focus on protecting automated financial platforms from adversarial manipulation and fraud, including document fraud detection and transaction monitoring. The company helps banks, insurance companies, payment platforms, and lenders secure digital transactions and perform identity forensics to guard against manipulation by organized fraudsters. By combining ML risk detection with ongoing monitoring, Resistant AI aims to enable responsible deployment of AI and machine learning while identifying, managing, and resolving risks associated with AI adoption and automated finance.
Sprinter Health
Series A in 2021 
Sprinter Health is a mobile healthcare provider that sends full-time nurses and phlebotomists to patients' homes for preventive care services.
Matter is a United States-based company that offers a social reading app designed to enhance the discovery and consumption of articles, blogs, and newsletters. By providing a platform that curates and organizes content, Matter aims to help users find high-quality information more efficiently. The app focuses on improving the reading experience by allowing users to engage with a diverse array of written material, facilitating a more informed and connected audience.
Vareto is a modern platform designed for strategic finance teams. It enables high-growth companies to power planning, reporting, and operational decision-making through real-time collaboration on financial models.
Altana Technologies
Series A in 2021 
Altana Technologies is a company that specializes in transforming both public and non-public data into an intelligent, interconnected map of the global supply chain. By utilizing its platform, Altana Atlas, the company enables enterprises, governments, and logistics providers to connect and collaborate, fostering trust and transparency across business networks. The platform offers comprehensive trade data management services by integrating internal and external data, providing clean data sets, and delivering real-time insights related to transactions, ownership, movements, and risks in the global trade network. Through advanced machine learning techniques, Altana Technologies equips organizations across various sectors with the tools to enhance the safety, efficiency, and profitability of trade, contributing to a more resilient, secure, and sustainable approach to globalization.
Ahana, founded in 2020 and based in San Mateo, California, specializes in developing ad hoc analytics solutions using PrestoDB. The company aims to make interactive analytics more accessible by simplifying the process for organizations of various sizes. Ahana also works to promote growth within the Presto community, building on its widespread use at large internet companies like Facebook, Uber, and Twitter.
Nym Health Inc., established in 2017 and headquartered in Boston, Massachusetts, specializes in medical coding technology for healthcare facilities. Its core product, Nym, is an autonomous coding solution that streamlines revenue cycle management. Nym reduces denials and operational expenses by directly billing and accurately assigning medical charge codes from patient charts, improving payment cycles and audit-readiness. It identifies relevant clinical aspects, assigns codes, and provides an audit trail explaining its coding decisions. With a research and development center in Tel Aviv-Yafo, Israel, Nym enables healthcare providers to enhance coding quality, lower costs, and focus more on patient care.
Xilis, Inc. is a biotechnology company founded in 2019 and based in Chapel Hill, North Carolina. The company specializes in developing next-generation organoid technologies aimed at guiding precision therapy for cancer patients and enhancing drug discovery processes. Its flagship platform, XilisµO, facilitates rapid diagnostics, personalized drug screening, and the creation of scalable patient-derived models, which support high-throughput drug discovery. By enabling both physicians and pharmaceutical companies to conduct tailored drug screenings, Xilis aims to lower costs and improve treatment outcomes for cancer patients.
Dyno Therapeutics
Series A in 2021 
Founded in 2018, Dyno Therapeutics specializes in developing adeno-associated virus (AAV) vectors for in vivo gene therapy delivery. The company's proprietary platform combines DNA synthesis of AAV capsids with sequencing and machine learning to create novel vectors tailored for safe, efficient, and targeted therapeutic solutions.
Nearby is a computer software company that facilitates connections between local businesses and nearby customers. It enables merchants to digitize their inventory and list their stores on a localized marketplace, enhancing visibility and accessibility. The platform not only generates demand for these businesses but also supports order fulfillment through various channels, including email campaigns, local delivery, and nationwide shipping. By bridging the gap between local merchants and their communities, Nearby aims to empower businesses to thrive in a competitive landscape.
Treeline Biosciences
Series A in 2021 
Treeline Biosciences is a biotechnology company focused on developing precision medicines for cancer and other serious diseases. Founded in 2021 and based in Stamford, Connecticut, the company uses a platform that integrates pathophysiology, genomics, and pattern recognition to identify therapeutic approaches that address unmet patient needs.
JP Traders
Series A in 2021 
Inkxpert Inc. is a marketing communications company that specializes in creating high-quality content tailored to various industries, including technology, healthcare, automobile, sports, lifestyle, fashion, education, and travel. The company focuses on understanding clients' products to design effective content for their marketing needs. Inkxpert offers a range of services, including technical research, content writing for marketing materials and websites, search engine optimization, social media management, case studies, and whitepapers. Each client is assigned a dedicated technical writing team, ensuring a quick turnaround time for project delivery, editing, and publishing.
DotPe is a technology startup founded in 2019, headquartered in Gurgaon, India. It offers a commerce and payments platform designed to enhance customer engagement and facilitate digital transformation for offline businesses. The platform enables companies to sell more efficiently, manage customers directly, and discover catalogs.